Adam Friedman, Ph.D.

Adam Friedman, Ph.D. has a diverse work experience that spans various roles and industries. Currently, they serve as a Strategic Advisor and Consultant at Atom Bioworks, where they provide guidance on the company's strategic aims and oversees the completion of a publication on their therapeutic successes in using proprietary nucleic acid scaffolds against Acute Myeloid Leukemia (AML).

Previously, Dr. Friedman held the position of Director of Research & Development at Atom Bioworks, leading the team to FDA pre-EUA for the application of Nucleic acid scaffold (Nas) technology in a SARS-CoV-2 lateral flow assay. Adam also designed and executed a Nas development program that resulted in the conversion of a patent on "Multispecific Polynucleotide Nanostructures for Cancer Detection and Therapy".

Dr. Friedman's experience also includes roles at Dencoda, LLC, where they served as a Strategic Advisor, and at Adivo Associates LLC, where they worked as a Senior Consultant and managed client accounts worth $1.5 million. Adam'sexpertise in the healthcare sector included areas such as hemophilia, anticoagulants, alpha-1 antitrypsin deficiency, and albumin.

Additionally, Dr. Friedman has an academic background. Adam served as an Adjunct Assistant Professor at the UNC Eshelman School of Pharmacy, where they co-investigated a student science enrichment program and served as a reviewer for the International Journal of STEM Education. Adam also held the position of Institute Fellow at the Eshelman Institute for Innovation, managing budgets and contributing to the institute's founding and administrative teams.

Earlier in their career, Dr. Friedman worked as an ORISE Post-baccalaureate Research Fellow at the FDA, where they focused on aptamer research and trained high school students as mentors. Adam also gained research experience as a Research Scientist Intern at Syntherica Corporation and a Research Assistant at the University of North Carolina at Chapel Hill, where they worked on projects related to bacterial species identification.

Overall, Dr. Adam Friedman, Ph.D. has a strong background in strategic advising, research and development, and consulting in the biotechnology and healthcare sectors.

Adam Friedman, Ph.D., obtained their Doctor of Philosophy (Ph.D.) degree in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, where they studied from 2010 to 2015. Prior to that, they earned a Master of Arts (M.A.) degree in History from East Carolina University, attending from 2005 to 2008. Adam's undergraduate education was at the University of North Carolina at Chapel Hill, where they obtained a Bachelor of Science (B.Sc.) degree in Biology, General, from 2001 to 2005. In addition to their formal education, they have also obtained several certifications. These include the "Initiating and Planning Projects" certification from Coursera in December 2017, the "Graduate Certificate in Translational Medicine" from the UNC School of Medicine's Graduate Training Program in Translational Medicine in December 2015, the "UNC TIBBS Essential Skills for Success in Industry Certificate" from the UNC Training Initiative in Biomedical and Biological Sciences in August 2012, and the "UNC TIBBS Summer Teaching Certificate" from the UNC Training Initiative in Biomedical and Biological Sciences in August 2011.